Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
In vivo acceleration of heart relaxation performance by parvalbumin gene delivery
Michael L. Szatkowski, … , Faris P. Albayya, Joseph M. Metzger
Michael L. Szatkowski, … , Faris P. Albayya, Joseph M. Metzger
Published January 15, 2001
Citation Information: J Clin Invest. 2001;107(2):191-198. https://doi.org/10.1172/JCI9862.
View: Text | PDF
Article

In vivo acceleration of heart relaxation performance by parvalbumin gene delivery

  • Text
  • PDF
Abstract

Defective cardiac muscle relaxation plays a causal role in heart failure. Shown here is the new in vivo application of parvalbumin, a calcium-binding protein that facilitates ultrafast relaxation of specialized skeletal muscles. Parvalbumin is not naturally expressed in the heart. We show that parvalbumin gene transfer to the heart in vivo produces levels of parvalbumin characteristic of fast skeletal muscles, causes a physiologically relevant acceleration of heart relaxation performance in normal hearts, and enhances relaxation performance in an animal model of slowed cardiac muscle relaxation. Parvalbumin may offer the unique potential to correct defective relaxation in energetically compromised failing hearts because the relaxation-enhancement effect of parvalbumin arises from an ATP-independent mechanism. Additionally, parvalbumin gene transfer may provide a new therapeutic approach to correct cellular disturbances in calcium signaling pathways that cause abnormal growth or damage in the heart or other organs.

Authors

Michael L. Szatkowski, Margaret V. Westfall, Carlen A. Gomez, Philip A. Wahr, Daniel E. Michele, Christiana DelloRusso, Immanuel I. Turner, Katie E. Hong, Faris P. Albayya, Joseph M. Metzger

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Immunofluorescence detection of parvalbumin in the heart. (a–h) The phot...
Immunofluorescence detection of parvalbumin in the heart. (a–h) The photographic montage assembled from representative serial cryosections extending from the apex to the base of a single heart at day 6 after gene transfer (representative of four experiments). (a and b) LV base sections; (c and d) LV midsection; (e–g) LV apical sections; (h) RV section. (h, inset) LV apical section from normal saline-injected control heart. Photographic exposure time was the same in a–h. There was extensive, parvalbumin-immunopositive reactivity in myocytes spanning the width, depth, and length of the left heart (apex to base). The primary antibody was anti-parvalbumin (PARV19; titer 1:500–1:1,000; Sigma Chemical Co.) and the secondary was goat anti-mouse IgG conjugated to Texas Red (titer 1:100; Molecular Probes Inc., Eugene, Oregon, USA), using methods described elsewhere (27). Dual labeling of single cells isolated from these hearts showed the colocalization of parvalbumin and sarcomeric actin, indicating that the cardiac myocytes were being transduced. Scale bar = 100 μm, a–h. (i) Low-power photomicrographs documenting the extent of lacZ gene expression (using X-gal, which results in blue staining of positive cells) after direct gene transfer to the heart in vivo. All panels are taken from the same gross dissection (sectioned in thirds) of a heart. Clockwise from left panel: side-view of apical one-third of heart with LV in foreground, demonstrating extensive transmural staining; side view of middle one-third of heart; side view of reconstruction of the apex/mid/base sections together; top view of midsection with base-facing section up (in this view, the spread of intense B-gal staining is evident across LV wall, with little or no detection in IVS or RV).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts